about
The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) PhenotypeTERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomasDifferentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature.Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomasMolecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors.TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromesHow to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid CancerParaganglioma of seminal vesicle and chromophobe renal cell carcinoma: a case report and literature review.Telomerase promoter mutations in cancer: an emerging molecular biomarker?The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.Helicobacter pylori's cholesterol uptake impacts resistance to docosahexaenoic acid.TERT biology and function in cancer: beyond immortalisation.Frequency of TERT promoter mutations in human cancers.TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.A clear cell renal cell carcinoma inhibiting the response to intravitreal antivascular endothelial growth factor therapy in wet age-related macular disease.Tumor-in-tumor of the thyroid with basaloid differentiation: a lesion with a solid cell nest neoplastic component?TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism.A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations.Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis?mTOR activation in medullary thyroid carcinoma with RAS mutation.Telomere Maintenance Mechanisms in Cancer.Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behaviour of bladder cancerC-Cell-Derived Calcitonin-Free Neuroendocrine Carcinoma of the ThyroidCribriform-Morular Variant of Papillary Thyroid Carcinoma Displaying Poorly Differentiated FeaturesSmall-Cell (Basaloid) Thyroid CarcinomaA novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney–Stratakis dyadAnalysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomasTERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer PatientsTERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinomaValidation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter StudyBiomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive ReviewGastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and MetabolismA 30-Year Long-Term Experience in Appendix Neuroendocrine Neoplasms-Granting a Positive Outcome
P50
Q28071562-91920454-E18C-4EC1-91D7-1EC694303188Q34313648-BDE4CFC2-6F5F-4F14-82B1-D573995E65D3Q35600108-8AC01BA3-7832-42C2-A76F-BC51DCDB99FFQ35731037-CC3604C3-1B12-4CDF-A504-EF983481375BQ36809668-5DB07243-106F-4A4F-8B58-F6141987610AQ37093384-F0415274-89A4-42D1-BD3E-D2F4D491F067Q37902072-D34EDFF7-F965-414B-8477-9D638A641880Q37985598-20F03934-4154-46F2-B18D-ED9FAAFE6ECDQ38232447-ADA4A574-2476-45E8-87B1-12FAAAA8C3B3Q38903424-1D2B2C14-3B9C-4F1C-8E54-6E4A2D174C26Q39032309-698635EC-5BF0-4CAE-B2C2-32112A77F76DQ39037274-14D22ED3-A0E9-4C62-953A-75077926371EQ39120274-66040D05-6C7C-42A2-A288-8E210FBA74BFQ42456732-2510EA9D-BD83-4465-9D21-742136DD7527Q42811031-06718D65-6128-4C4D-B676-0B5B01568E7CQ42913067-DA6113B1-AB78-4BDA-ACD2-08B703B999A6Q44819624-D35F60B1-38F7-4242-A39A-1E61A006C1C2Q51092203-FED11123-1ADE-451E-820A-D13C6F683BFFQ54475618-75B4E023-FAF1-49B6-A3AF-57677B0B6415Q54716120-0AD7775F-8D52-4A23-99DD-F08063E42ADDQ55068563-B8810448-F456-489C-B96F-CDA8B91BFB14Q55071575-9ECB1421-7664-4173-BC2E-B3751FF2E485Q55443450-7C47F746-A5D8-4A51-93FF-D0050EE132AAQ57797239-784EF9BB-030C-440D-B68A-D0E27F4D6906Q59600675-A34AE410-164E-4C6A-8EF0-68BF8DCE8052Q59600687-9CF8F36E-3BA5-4AFD-BE0C-2BFA82C5E688Q59600705-D44D17B4-29BB-4827-B13F-FAD83DC2141CQ60526951-9AD6F54A-7DD5-4A18-B840-684E4D50478DQ60527002-636B2FE7-DC91-4604-B48C-CC348583315FQ89551068-1054F320-73D1-4931-B817-E1019F4EB223Q91232481-8E36B4D2-8217-423F-BAB2-075E8FE8EBC7Q92539491-21C1534F-BAB2-4DF3-B427-3C1BB554B6EAQ92663356-713DD49E-44A2-474C-BC27-26EC00C5AB09Q95729496-57370DD3-F40A-4A65-9160-2AED03B6058EQ95931114-30A99F60-CB63-4B45-8B4A-6F37B7D35FA7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
João Vinagre
@ast
João Vinagre
@en
João Vinagre
@es
João Vinagre
@nl
João Vinagre
@pt
João Vinagre
@sl
type
label
João Vinagre
@ast
João Vinagre
@en
João Vinagre
@es
João Vinagre
@nl
João Vinagre
@pt
João Vinagre
@sl
prefLabel
João Vinagre
@ast
João Vinagre
@en
João Vinagre
@es
João Vinagre
@nl
João Vinagre
@pt
João Vinagre
@sl
P1053
J-7431-2013
P106
P1153
35186647000
P21
P31
P3829
P496
0000-0002-0871-1427